Credit Suisse sees PTC Therapeutics as a top stock pick

5 December 2014

Credit Suisse has released a biotech research report from analysts Jason Kantor and Jeremiah Shepard that has their top picks for upside potential in the biotech segment for 2015.

The analyst firm updated its top picks to PTC Therapeutics (Nasdaq: PTCT) and Esperion Therapeutics (Nasdaq: ESPR), while removing Regeneron Pharmaceuticals (Nasdaq: REGN) from the top picks list. Both top picks have significant clinical and regulatory milestones, and both have unpartnered global rights, which could ultimately drive premium acquisitions. Credit Suisse sees shares perhaps doubling in 2015.

First, PTC has become substantially de-risked with the European approval of Translarna (ataluren) for the treatment of muscular dystrophy (DMD; The Pharma Letter August 4). Credit Suisse has high confidence in the fully enrolled confirmatory Phase III trial for DMD that is expected to read out in October 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK